Nemocnica Poprad a.s.

Clinical research in this area focuses on serious bacterial infections, especially complicated urinary tract infection and acute pyelonephritis. The studies are designed to assess whether new oral treatment options can match or improve upon established hospital therapies, with the goal of supporting effective infection control and better patient recovery.

• Testing a new oral antibiotic approach for hospitalized adults with cUTI and AP
• Comparing treatment effectiveness against standard intravenous care
• Evaluating overall clinical and microbiological response in difficult-to-treat infections

Work at the Poprad site adds to broader efforts to improve practical treatment choices for complex infections.

This research portfolio includes studies in heart failure and broader atherosclerotic cardiovascular disease. The trials aim to understand whether new therapies can reduce major heart and vascular events, ease the burden of heart failure, and improve outcomes for people living with high cardiovascular risk or obesity-related complications.

• Investigating treatment options for heart failure with preserved or mildly reduced ejection fraction and obesity
• Assessing strategies to lower the risk of heart attack, stroke, and other serious vascular events
• Supporting better prevention and long-term management of cardiovascular disease

These studies reflect a strong focus on improving both symptom control and event prevention in cardiovascular care.

Clinical trials in ophthalmology at this site address vision-threatening conditions such as diabetic macular edema and wet age-related macular degeneration. The main purpose is to evaluate whether new eye treatments can preserve or improve visual acuity while offering effective alternatives to existing therapies.

• Studying treatments for DME to compare vision outcomes with current standards
• Testing new approaches for wet age-related macular degeneration
• Focusing on better control of retinal disease and protection of sight

At Nemocnica Poprad a.s., this work supports ongoing advances in retinal disease management and vision preservation.